miR‐29c regulates resistance to paclitaxel in nasopharyngeal cancer by targeting ITGB1
Sign Up to like & getrecommendations! Published in 2019 at "Experimental Cell Research"
DOI: 10.1016/j.yexcr.2019.02.012
Abstract: &NA; Paclitaxel (Taxol) is an anticancer taxane drug commonly used in the treatment of nasopharyngeal carcinoma (NPC). However, resistance to paclitaxel is a major difficulty in developing an effective therapy against NPC. MicroRNAs (miRNAs) are… read more here.
Keywords: npc; taxol; resistance; resistance paclitaxel ... See more keywords
The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.23008
Abstract: Interleukin 17B (IL-17B) is a pro-inflammatory cytokine that belongs to the IL-17 cytokines family and binds to IL-17 receptor B (IL-17RB). Here we found that high expression of IL-17B and IL-17RB is associated with poor… read more here.
Keywords: breast; breast cancer; pathway; resistance paclitaxel ... See more keywords